Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Trial of Candesartan + Amlodipine Combination (CKD-330) vs Components Alone in Essential Hypertension
KCT0001846Phase 2Completed
- Sponsor
- Chong Kun Dang
- Start
- Apr 2014
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in essential hypertension comparing CKD-330 combination arm, candesartan monotherapy arm and amlodipine monotherapy arm (3 arms). Started Apr 2014; status: completed.
02
Drugs
candesartan + amlodipinecandesartanamlodipine
03
Conditions
essential hypertension
Beyond the preview
Go deeper on KCT0001846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0001846.